We recently located a rare cytokeratin-positive (CK+) type of microvascular endothelial cell (MVEC) in the corpus luteum and aorta. Bovine corpus luteum MVEC are known to be involved in the cyclic accumulation of eosinophils and macrophages. Since leukocyte migration is specifically mediated by adhesion molecules and the release of cytokines, we compared the expression of these factors in basal and TNF-α-stimulated CK+ MVEC and in common cytokeratin-negative (CK–) MVEC in order to obtain an initial insight into the functional capacities of CK+ MVEC. CK– MVEC revealed significantly higher basal RANTES mRNA expression than CK+ MVEC, and TNF- α up-regulated RANTES mRNA in both types of MVEC. Only resting and stimulated CK– MVEC expressed granulocyte-macrophage colony-stimulating factor mRNA. Both MVEC types expressed monocyte colony-stimulating factor mRNA, but remained negative for eotaxin and interleukin (IL)-5 mRNA even after stimulation. Resting CK+ MVEC were positive for CD29, CD31, CD49a and CD49e, but expressed most of these antigens at a significantly lower density than did CK– MVEC. In contrast to CK– MVEC, CK+ MVEC failed to express CD49b or MHC class II. The activation of CK+ MVEC with TNF-α induced the expression of CD62P, but not of CD49b or MHC class II. In summary, phenotypically variable MVEC derived from the microvascular bed of one organ differ in their TNF-α-regulated expression of cytokine mRNA and adhesion molecules. Morphological heterogeneity is related to a particular specialisation of functional MVEC.

Keywords:
Endothelial cell, Cytokeratin, Corpus luteum
1.
Thorin E, Shreeve SM: Heterogeneity of vascular endothelial cells in normal and disease states. Pharmacol Ther 1998;78:155–166.
2.
Geiger M, Stone A, Mason SN, Oldham KT, Guise KS: Differential nitric oxide production by microvascular and macrovascular endothelial cells. Am J Physiol 1997;273:L275–L281.
3.
Fenyves AM, Behrens J, Spanel-Borowski K: Cultured microvascular endothelial cells (MVEC) differ in cytoskeleton, expression of cadherins and fibronectin matrix. A study under the influence of interferon-gamma. J Cell Sci 1993;106:879–890.
4.
Spanel-Borowski K, Fenyves A: The heteromorphology of cultured microvascular endothelial cells. Arzneimittelforschung 1994;44:385–391.
5.
Spanel-Borowski K, Ricken AM, Patton WF: Cytokeratin-positive and cytokeratin-negative cultured endothelial cells from bovine aorta and vena cava. Differentiation 1994;57:225–234.
6.
Ricken AM, Spanel-Borowski K, Saxer M, Huber PR: Cytokeratin expression in bovine corpora lutea. Histochem Cell Biol 1995;103:345–354.
7.
Spanel-Borowski K, van der Bosch J: Different phenotypes of cultured microvessel endothelial cells obtained from bovine corpus luteum. Study by light microscopy and by scanning electron microscopy (SEM). Cell Tissue Res 1990;261:35–47.
8.
Jahn L, Fouquet B, Rohe K, Franke WW: Cytokeratins in certain endothelial and smooth muscle cells of two taxonomically distant vertebrate species, Xenopus laevis and man. Differentiation 1987;36:234–254.
9.
Mineau-Hanschke R, Patton WF, Hechtman HB, Shepro D: Immunolocalization of cytokeratin 19 in bovine and human pulmonary microvascular endothelial cells in situ. Comp Biochem Physiol Comp Physiol 1993;104:313–319.
10.
Reibiger I, Spanel-Borowski K: Differences in selective localisation of eosinophils in the bovine ovary in comparison to mast cells. Exp Clin Endocrinol Diabetes 1999;107:47.
11.
Brnnstrom M, Pascoe V, Norman RJ, McClure N: Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertil Steril 1994;61:488–495.
12.
Best CL, Pudney J, Welch WR, Burger N, Hill JA: Localization and characterization of white blood cell populations within the human ovary throughout the menstrual cycle and menopause. Hum Reprod 1996;11:790–797.
13.
Spanel-Borowski K, Rahner P, Ricken AM: Immunolocalization of CD18-positive cells in the bovine ovary. J Reprod Fertil 1997;111:197–205.
14.
Burke-Gaffney A, Hellewell PG: Eotaxin stimulates eosinophil adhesion to human lung microvascular endothelial cells. Biochem Biophys Res Commun 1996;227:35–40.
15.
Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H, Bochner BS, Schleimer RP: Cutaneous injection of RANTES causes eosinophil recruitment: Comparison of nonallergic and allergic human subjects. J Immunol 1997;159:2962–2972.
16.
Marfaing-Koka A, Devergne O, Gorgone G, Portier A, Schall TJ, Galanaud P, Emilie D: Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 1995;154:1870–1878.
17.
Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS: Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J Interferon Cytokine Res 1999;19:91–104.
18.
Vinatier D, Dufour P, Tordjeman-Rizzi N, Prolongeau JF, Depret-Moser S, Monnier JC: Immunological aspects of ovarian function: Role of the cytokines. Eur J Obstet Gynecol Reprod Biol 1995;63:155–168.
19.
Sopp P, Howard CJ: Cross-reactivity of monoclonal antibodies to defined human leucocyte differentiation antigens with bovine cells. Vet Immunol Immunopathol 1997;56:11–25.
20.
Aust G, Lehmann I, Laue S, Scherbaum WA: Activated and interferon-gamma producing thyroid-derived T cells are detected in Graves’ disease, thyroid autonomy as well as in non-toxic multinodular goiter. Eur J Endocrinol 1996;135:60–68.
21.
Celi FS, Zenilman ME, Shuldiner AR: A rapid and versatile method to synthesize internal standards for competitive PCR. Nucleic Acids Res 1993;21:1047.
22.
Aust G, Brylla E, Lehmann I, Kiessling S, Spanel-Borowski K: Cloning of bovine RANTES mRNA and its expression and regulation in ovaries in the periovulatory period. FEBS Lett 1999;463:160–164.
23.
Köhler T, Rost AK, Remke H: Calibration and storage of DNA competitors used for contamination-protected competitive PCR. Biotechniques 1997;23:722–726.
24.
Albelda SM, Oliver PD, Romer LH, Buck CA: EndoCAM: A novel endothelial cell-cell adhesion molecule. J Cell Biol 1990;110:1227–1237.
25.
Tedder TF, Steeber DA, Chen A, Engel P: The selectins: Vascular adhesion molecules. FASEB J 1995;9:866–873.
26.
Mutin M, Dignat-George F, Sampol J: Immunologic phenotype of cultured endothelial cells: Quantitative analysis of cell surface molecules. Tissue Antigens 1997;50:449–458.
27.
Grooby WL, Krishnan R, Russ GR: Anti-ovine VCAM-1 monoclonal antibodies inhibit adhesion and proliferation between sheep endothelial and mononuclear cells in vitro. Immunol Cell Biol 1997;75:546–553.
28.
Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD: Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449–456.
29.
Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB: Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507–3516.
30.
Hogan SP, Foster PS: Cellular and molecular mechanisms involved in the regulation of eosinophil trafficking in vivo. Med Res Rev 1996;16:407–432.
31.
Coleman DL, Chodakewitz JA, Bartiss AH, Mellors JW: Granulocyte-macrophage colony-stimulating factor enhances selective effector functions of tissue-derived macrophages. Blood 1988;72:573–578.
32.
Flanagan AM, Lader CS: Update on the biologic effects of macrophage colony-stimulating factor. Curr Opin Hematol 1998;5:181–185.
33.
Hamilos DL, Leung DY, Huston DP, Kamil A, Wood R, Hamid Q: GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP). Clin Exp Allergy 1998;28:1145–1152.
34.
Aust G, Brylla E, Lehmann I, Kiessling S, Spanel-Borowski K: Different cytokine, adhesion molecule and prostaglandin receptor expression by cytokeratin 18 negative (CK–) and positive (CK+) endothelial cells (EC). Basic Res Cardiol 1999;94:406.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.